MAT stands for medication-assisted treatment. MOUD stands for medications for opioid use disorder. In opioid use disorder care, MAT and MOUD often refer to the same FDA-approved medications: buprenorphine, methadone, and naltrexone. MOUD is the more precise term — it names the condition being treated and avoids implying that medication is only an “assist”.
What does MAT mean?
MAT is the older term. It was used in U.S. policy and clinical settings for decades. It describes the use of FDA-approved medications — buprenorphine (Suboxone, Subutex, Sublocade), methadone, and naltrexone (Vivitrol) — in combination with counseling and behavioral therapies for substance use disorders.
The assisted part of MAT was meant to signal that medication is part of a broader treatment plan that includes other components.
Why did the field shift to MOUD?
The shift came from clinicians, researchers, and patient advocates who argued that medication-assisted treatment implies the medication is secondary — an “assist” to the “real” treatment. The evidence supports medication as a core treatment for opioid use disorder, not merely an add-on. Counseling and behavioral support can help many patients, but access to medication should not depend on completing counseling, group visits, or behavioral milestones.
For opioid use disorder, the medications themselves — buprenorphine and methadone in particular — have the strongest evidence base for reducing overdose deaths and improving long-term outcomes. SAMHSA notes that buprenorphine should not be withheld because a patient cannot or will not participate in counseling. Counseling and behavioral support add value when patients want them, but they should not be a barrier to receiving medication.
MOUD — medications for opioid use disorder — treats the medication as the treatment. ASAM, NIDA, and SAMHSA have largely shifted to MOUD in recent guidance.
Why does the language matter?
Three reasons:
- Stigma. “Assisted” implies the medication is a crutch — or that the “real” goal is to come off it eventually. For many patients with chronic opioid use disorder, that is not the right framing. Insulin is not an “assist” for a person with diabetes.
- Access. Some clinics that called themselves “MAT” programs required mandatory counseling, group attendance, or specific behavioral milestones to remain on medication. The MOUD framing supports access to medication on the basis of clinical need, not on whether a patient completes other components.
- Outcomes. The strongest evidence is for the medications themselves. Patients who do not want or cannot access counseling still benefit from buprenorphine.
What about MOUD versus MAT in policy?
Federal agencies use both terms in different documents, but recent SAMHSA, NIDA, and ASAM guidance has shifted toward MOUD. Some legacy programs still use MAT. The medications are the same.
If you see either term, it refers to the same FDA-approved treatments.
What about MAUD or other terms?
MAUD (medications for alcohol use disorder) is the parallel term for naltrexone, acamprosate, and disulfiram — the FDA-approved medications for alcohol use disorder. Same logic applies: the medications are the treatment.
Is MAT an incorrect term?
Not exactly. MAT is still common in older policy documents, clinics, and insurance language. MOUD is usually preferred in current clinical writing because it is more precise and less likely to imply that medication is secondary. AHRQ’s MOUD implementation resource specifically uses MOUD and avoids potentially stigmatizing terms, while recognizing legacy MAT terminology.
